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he Coalition against Typhoid (CaT): addressing barriers to
yphoid vaccine implementation
. Nelson ∗, C. de Quadros
Sabin Vaccine Institute, Washington, DC, USA
Background: Typhoid fever continues to be a major public
ealth problem. In endemic communities and during outbreaks,
nfants, toddlers and young children are disproportionately
ffected.WHOestimates 21million cases and216,000deaths occur,
nnually.Whileoutbreak reports are common, estimatesof typhoid
urden have been limited by the absence of standardized surveil-
ance, especially in sub-Saharan Africa.
Methods: Effective case management can reduce case-fatality
ates. However, widespread and increasing prevalence of mul-
idrug (MDR) resistance and nalidixic-acid-resistance (NAR) have
educedeffective treatmentoptions, increased costs and resulted in
igher ratesof seriouscomplicationsanddeaths. Ingeneral, surveil-
ance and case management is limited by the poor performance of
yphoid diagnostics. Typhoid vaccines – oral live attenuated Ty21a
nd injectable Vi polysaccharide – are safe and efﬁcacious. In 2011,
HO granted prequaliﬁcation to a Vi polysaccharide vaccine.
Results: The programmatic use of typhoid vaccines is a global
ealth priority supported by WHO and prioritized by the GAVI
lliance. WHO SEARO has prioritized typhoid vaccines for immedi-
te introduction and the Indian Academy of Pediatrics recommends
he use of ViPS vaccines in children 2-15y. Despite this, the imple-
entation of typhoid vaccines as part of national or municipal
mmunization programs has been slow.
The Coalition against Typhoid (CaT) was established in 2009 to
ddress the barriers to typhoid vaccine adoption. These include:
imited local surveillance and poor diagnostics; low awareness
f the widespread and increasing prevalence of MDR and NAR
yphoid; and low awareness of the successful use of vaccines to
ontrol disease.
Conclusion: Typhoid vaccines are inexpensive, vaccination
trategies are cost-effective, and there is high demand for vaccine
n affected populations. Recognizing the need for vaccines that are
afe and effective in infants/young populations and that provide
ong lasting and high levels of protection, typhoid conjugate vac-
ines are currently in clinical development, with some focused on
ffering combined protection against S. Typhi and S. Paratyphi. The
ontrol of enteric fever caused by S. Typhi is a global health prior-
ty. Safe, effective and affordable vaccines can be used as part of
comprehensive and integrated strategy to control typhoid fever.
ww.COALITIONagainstTYPHOID.org
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Production of tissue culture rabies vaccine for human use in
Nepal
G.R. Pant
Rabies Vaccine Production Laboratory, Kathmandu, Nepal
Background: A trail batch of tissue culture inactivated anti
rabies vaccine was produced at Rabies Vaccine production Labora-
tory in Kathmandu in 2010 by using Vero cell. The potency (IU/ml)
of this vaccinewas 4.6when tested inNancyWild Life Laboratory in
France. The result of other quality test such as inactivation, toxicity,
safety, speciﬁcity, sterility and pH test were found satisfactory.
Methods: Vero working cell line (164P) was used for propa-
gation of cell that was infected with PV/RV at 100 MOI working
rabies virus strain at 170 serial passages of cells. Virus cultures
ﬂuid was harvested and pooled sample of ﬂuid was tested by using
Anigen Rapid Test Kit for the detection of rabies virus. Pooled sam-
ple was found positive for rabies virus antigen where as the ﬂuid
collected from control cell was negative for rabies virus. The har-
vested viruswas then centrifuged at 10,000 rpm and condensed for
puriﬁcation in pellicon machine (milli pore) under Pump Master
ﬂex speed 0.5, feed pressure 0.2 Kg/cm2 and pellicon ﬁlter mem-
brane 0.02 um pore size. The titer of virus before inactivation was
10 7.5 TCID 50/0.1ml. Finally this virus ﬂuid was inactivated with
beta propiolactone
Results: The titer of virus before inactivation was 10 7.5 TCID
50/0.1ml. Finally this virus ﬂuid was inactivated with beta propio-
lactone. The ED 50 of the titer of vaccine was 10 when challenged
with CVS 50 LD50 /0.03ml in NIH test. The potency (IU/ml) of
this vaccine was 4.6 when tested in Nancy Wild Life Laboratory in
France. The result of other quality test such as inactivation, toxicity,
safety, speciﬁcity, sterility and pH test were found satisfactory.
Conclusion: Vaccine is satisfactory for human use.
http://dx.doi.org/10.1016/j.ijid.2012.05.1007
Type: Poster Presentation
Final Abstract Number: 48.026
Session: Vaccines & Vaccine Development
Date: Friday, June 15, 2012
Time: 12:45-14:15
Room: Poster & Exhibition Area
ModeofAction (MoA) studies contribute to the safetyevaluation
of AS04 adjuvanted vaccines
S. Preiss, M. Mergaerts, A. Di Pasquale ∗, N. Garcon
GlaxoSmithKline Biologicals, Wavre, Belgium
Background:By incorporating novel adjuvants into vaccine for-
mulationswe aim to enhance and guide immune responses elicited
against the vaccine antigen. Vaccines undergo a continuous and
rigorous safety assessmentduringdevelopmentandafter licensure.
Increased knowledge regarding the safety of adjuvanted vac-
cines, collected from the adjuvant’s mode of action (MoA)
